Cargando…
Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials
BACKGROUND: We conducted a systematic review and meta-analysis to clarify the risk of early and late cardiotoxicity of anthracycline agents in patients treated for breast or ovarian cancer, lymphoma, myeloma or sarcoma. METHODS: Randomized controlled trials were sought using comprehensive searches o...
Autores principales: | Smith, Lesley A, Cornelius, Victoria R, Plummer, Christopher J, Levitt, Gill, Verrill, Mark, Canney, Peter, Jones, Alison |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2907344/ https://www.ncbi.nlm.nih.gov/pubmed/20587042 http://dx.doi.org/10.1186/1471-2407-10-337 |
Ejemplares similares
-
Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents
por: Briasoulis, Alexandros, et al.
Publicado: (2022) -
Cardiotoxicity of Anthracyclines
por: Cardinale, Daniela, et al.
Publicado: (2020) -
Anthracycline-induced cardiotoxicity and senescence
por: Booth, Laura K., et al.
Publicado: (2022) -
Anthracycline Chemotherapy and Cardiotoxicity
por: McGowan, John V, et al.
Publicado: (2017) -
The role of iron in anthracycline cardiotoxicity
por: Gammella, Elena, et al.
Publicado: (2014)